Primary aldosteronism (PA) has been recognized as a

Aldosterone, Plasma Renin Activity, and Aldosterone/Renin Ratio in a Normotensive Healthy Pediatric Population Alejandro Martinez-Aguayo, Marlene Aglony, Carmen Campino, Hernan Garcia, Rodrigo Bancalari, Lillian Bolte, Carolina Avalos, Carolina Loureiro, Cristian A. Carvajal, Alejandra Avila, Viviana Perez, Andrea Inostroza, Carlos E. Fardella Downloaded from http://hyper.ahajournals.org/ by guest on May 9, 2018 Abstract Primary aldosteronism is an important cause of secondary hypertension and is suspected in adults with an aldosterone/renin ratio 25. The normal aldosterone/renin ratio is unknown in children. The aim was to establish serum aldosterone, plasma renin activity, and aldosterone/renin ratio values in a healthy pediatric population. A cross-sectional study was performed in 211 healthy normotensive children (4 to 16 years old). Two subgroups of normotensive children were obtained: with hypertensive parents (NH) (n 113) and normotensive parents (n 98). Blood samples for measuring serum aldosterone, plasma renin activity, aldosterone/renin ratio, and DNA were collected. In subjects with aldosterone/renin ratio 25, the chimeric CYP11B1/CYP11B2 gene was investigated by long-extension PCR. Results are expressed as median [Q 1 Q 3 ]. NH and normotensive parents groups were similar in serum aldosterone (6.5 [3.6 to 9.0] ng/dl versus 6.5 [2.9 to 9.7] ng/dl; P 0.968) and plasma renin activity (2.3 [1.6 to 3.1] versus 2.4 [1.7 to 3.7] ng/ml per hour; P 0.129). The aldosterone/renin ratio was higher in the NH group, but this difference did not reach statistical significance (2.8 [1.9 to 4.1] versus 2.5 [1.4 to 4.0], P 0.104). In one subject of the NH group, the chimeric CYP11B1/CYP11B2 gene was detected. We demonstrated that normal aldosterone/renin ratio values in a healthy pediatric population without NH were lower than those reported for an adult normotensive population. (Hypertension. 2010;56:391-396.) Key Words: primary aldosteronism plasma renin activity arterial hypertension aldosterone/plasma renin activity ratio Primary aldosteronism (PA) has been recognized as a cause of hypertension since the 1950s. When the first case was reported, one of the most important characteristics was the presence of a severe hypertensive profile associated with hypokalemia. 1 In recent years, the importance of diagnosing PA has become clear for its ability to induce hypertension, as well as the deleterious effects of aldosterone in various organs, including effects on the heart and blood vessels via nonepithelial receptors, independent of changes in blood pressure (BP). 2,3 In 1976, Dunn and Espiner 4 first suggested simultaneous measurements of serum aldosterone (SA) concentration and plasma renin activity (PRA), as well as the aldosterone/renin ratio (ARR) as a potentially useful screening test for PA. The ARR has been considered a useful tool in screening for PA. 5 9 The prevalence of PA increased from 1% when hypokalemia was used for screening to close to 10% when the ARR was used for screening, and this value was even higher in patients with severe or resistant hypertension. 10 13 The ARR by itself, however, does not result in a definitive diagnosis of PA. A confirmatory test is necessary, and 30 to 50% of patients with a positive ARR could display aldosterone levels that are normally suppressed after confirmatory testing. 14 Today, different groups have established the ARR cut-off in adults to be between 20 to 40 when SA is measured in ng/dl, and PRA is measured in ng/ml per hour. 5 7,15,16 However, this value has not been validated in children and adolescents. Data regarding the prevalence of PA and the normal parameters of the renin angiotensin system, especially the ARR, are unknown for pediatric nonhypertensive individuals. The high prevalence of PA in the general hypertensive population 16 18 allows us to postulate that PA may begin in the pediatric population prior to the development of hypertensive and vascular damage. Furthermore, up to 4% of school children are hypertensive, 19,20 and the magnitude of the burden of hypertension requires increased awareness, treatment, and control. These considerations argue for greater efforts toward demonstrating any underlying cause of hypertension in order to facilitate early specific treatment that Received April 19, 2010; first decision May 8, 2010; revision accepted July 12, 2010. From the Departments of Pediatrics (A.M.-A., M.A., H.G., R.B., L.B., C.L., V.P.), Endocrinology (C.C., C.A.C., C.E.F.), Nephrology (A.I.), Pontificia Universidad Católica de Chile, Santiago, Chile; Department of Pediatrics (C.A.), Universidad de Antofagasta, Antofagasta, Chile; Institute of Maternal and Child Research (A.A.), Faculty of Medicine, University of Chile, Santiago, Chile. M.A. and A.M.-A. contributed equally to this work. Correspondence to Carlos Fardella, Department of Endocrinology, School of Medicine, Pontificia Universidad Católica de Chile, Lira 85, Piso 5, Santiago 8330074, Chile. E-mail cfardella@med.puc.cl 2010 American Heart Association, Inc. Hypertension is available at http://hyper.ahajournals.org DOI: 10.1161/HYPERTENSIONAHA.110.155135 391

392 Hypertension September 2010 Downloaded from http://hyper.ahajournals.org/ by guest on May 9, 2018 might decrease cardiovascular risk and, in cases confirmed as having a genetic basis, to enable genetic counseling. 21 Our objectives were to establish the SA, PRA, and ARR levels in a pediatric normotensive healthy population. Subjects and Methods A cross-sectional study was designed. Chilean children and adolescents of both sexes, ranging from 4 to 16 years old, were invited to participate. We recruited patients from lower-middle, middle, and high socioeconomic status. All subjects were evaluated at the pediatric endocrinology and nephrology clinics of the Pontificia Universidad Católica de Chile from July 2009 to March 2010. Two hundred thirty-eight subjects agreed to participate in the study. A complete physical examination was performed for all of them by 2 pediatric endocrinologists (A.M.-A. and H.G.), 1 pediatric nephrologist (M.A.), and 4 pediatricians with training in pediatric endocrinology (C.A., L.B., R.B., and C.L.). Height was measured using a wall-mounted Harpenden stadiometer (Holtain). Weight and total fat mass percentage were also assessed by bioelectrical impedance (Tanita Corporation of America). Subjects with severe obesity (z score, 2.5) were excluded. Pubertal development was assessed according to the method of Marshall and Tanner. 22 Trained nurses measured the BP and heart rate of all of the subjects and their parents. Three measurements were taken consecutively in the right arm at 5-minute intervals, while the patient was in a seated position, using an oscillometric method (Dinamap CARESCAPE V100, GE Healthcare). This was done following the published recommendations 23,24 with a cuff and bladder size adjusted to upper-arm girth. The office BP of children and their parents was classified according the Fourth Report of Task Force and JNC 7 (The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure) guidelines. 23,24 In addition to measuring BP, an adult was considered hypertensive if there was a history of hypertension on treatment. Normotension in children was defined as an average systolic BP (SBP) and/or diastolic BP less than the 90th percentile for gender, age, and height. We calculated the BP index so that we could compare children from different gender, age, and stature percentiles. The BP index was determined using the observed BP/50th percentile BP level for gender, age, and stature using the normal values reported; 23 for more details, please see the supplemental data, available online at http://hyper.ahajournals.org. All the subjects with elevated BP were confirmed using the auscultatory method. Children with prehypertension or hypertension were excluded. We measured serum creatinine (Cr), calcium, urea, glucose, and a hepatic profile (alkaline phosphatase, bilirubin, alanine aminotransferase, aspartate aminotransferase, and albumin) in all subjects. We used this screening to exclude subjects with renal disease, diabetes mellitus, hepatic failure, and hypercalcemia. With the aim of reducing the chances of, to including children with, endogenous hypercortisolism, we excluded those subjects with combined reduced linear growth and increased weight; these elements have quite high sensitivity in identifying subjects at risk of having endogenous hypercortisolism. 25 We also excluded children who were undergoing any treatment that might affect the renin-angiotensin system or taking antihypertensive drugs at the time of the diagnosis. A total of 211 healthy normotensive children were enrolled. Following an overnight fast, basal blood samples were obtained between 8:00 and 10:00 AM to measure sodium, potassium, SA, PRA, and ARR (subjects were in the sitting position with at least a 15-minute rest). The blood samples were drawn from an indwelling catheter positioned in an antecubital vein, and they were separated immediately after collection. At the same time, 12-hour nocturnal urine (between 7:00 PM and 7:00 AM) samples were collected. Total 12-hour urine volumes were measured, and 50-mL aliquots were stored to measure urinary-free cortisol (UFF), Cr, sodium, and potassium. We also calculated the fractional excretion of sodium. The serum, plasma, and urine samples were stored at 70 C until analysis. Patients without a full sample at the 12-hour urine collection were not included in this analysis. The protocol was approved by the Ethical Committee of the Faculty of Medicine of the Pontificia Universidad Católica de Chile in accordance with the Helsinki Declaration. All parents signed informed consent forms, and subjects older than 7 years old gave their assent before entering the study. Hormonal and Biochemical Assays The results were expressed in SI units according the instructions of the journal. However, for SA, we use ng/dl (and pmol/l in parentheses), and for PRA, we use ng/ml per hour instead of g/l per hour. SA was measured by radioimmunoassay using a commercial kit from Diagnostic Products. The intraassay and interassay coefficients of variation were 5.1 and 7.1%, respectively. PRA was determined as previously described by Menard and coworkers. 26 The intraassay and interassay coefficients of variation were 6.1 and 8.2%, respectively. 27 The lower limit of the PRA assay was 0.1 ng/ml per hour. 28 Serum cortisol and UFF were measured by immunoassay in automated equipment (IMMULITE 2000; Siemens Healthcare Diagnosis, Inc). The intraassay coefficients of variation were 6.8 and 8.7%, respectively. Serum and urinary Cr were measured by the Jaffe method in automated equipment (Modular Analytics; Roche). UFF was normalized by Cr (UFF/Cr), and kidney function was estimated using serum Cr levels. Genetic Study In subjects with an ARR 25, a genetic study was performed to determine the presence of familial hyperaldosteronism type I (no. 103900; Online Mendelian Inheritance in Man). Genomic DNA was isolated from peripheral blood leukocytes and purified by a commercial kit (Qiagen). The genetic study was carried out by long-extension PCR of the chimeric gene CYP11B1/CYP11B2 using a protocol previously described by Jonsson et al 29 and modified by MacConnachie et al. 30 Data Analysis Two subgroups of subjects were defined according to the BP of their parents: normotensive children with hypertensive parents (NH) and normotensive children with normotensive parents (NN). Results were expressed as median values (interquartile range, [Q 1 Q 3 ]). Statistical analyses were performed using the SPSS 15.0 program for Windows (SPSS, Inc). The comparison between NH and NN groups was performed using the Mann Whitney U test. The measurements of SA, PRA, and ARR were logarithmically transformed to achieve a normal distribution before Pearson association analysis. We also performed partial correlation analysis to find the association between 2 variables after removing the effects of other variables. Correlations involving the Tanner pubertal state were performed using Spearman s correlation, and probability values 0.05 were considered as statistically significant. Results Of the 211 normotensive children selected to participate in this study, 113 children had at least 1 hypertensive parents (NH group), and 98 children had normotensive parents (NN group). In the NH group, 60.2% of the parents were receiving treatment: 41% with angiotensin-converting enzyme inhibitors, 28% with angiotensin II receptor blockers, 20% with blockers, 13% with diuretics, and 8% with calcium channel blockers. In some cases, combination therapy was prescribed. Clinical and biochemical characteristics of the total group, as well as the subgroups, are shown in Table 1. Clinical Characteristics The subjects distributions by gender, age, height, body mass index, and percentage of body fat were similar between the

Martinez-Aguayo et al Aldosterone/Renin Ratio in Normotensive Children 393 Table 1. Clinical and Biochemical Characteristics of Children Stratified by Parental BP Status Downloaded from http://hyper.ahajournals.org/ by guest on May 9, 2018 Characteristics Total Group (n 211) NH Group (n 113) NN Group (n 98) Clinical Gender, % female 113 (53.6) 62 (54.9) 51 (52.0) Age, years 11.1 [8.9 to 12.9] 11.3 [9.2 to 13.1] 11.0 [8.6 to 12.8] Height, SDS 0.22 [ 0.40 to 0.83] 0.14 [ 0.45 to 1.06] 0.3 [ 0.37 to 0.79] BMI, percentile 80.5 [52.5 to 93.9] 81.0 [44.9 to 94.2] 79.3 [55.4 to 93.2] Body fat mass, % 24.4 [16.8 to 34.3] 23.5 [16.5 to 34.5] 25.3 [16.7 to 33.3] SBP index 1.03 [0.98 to 1.07] 1.04 [0.99 to 1.01] 1.01 [0.96 to 1.06]* DBP index 1.07 [0.99 to 1.134] 1.08 [0.99 to 1.07] 1.06 [0.99 to 1.13] Biochemical SA, ng/dl 6.5 [3.4 to 9.4] 6.5 [3.6 to 9.0] 6.5 [2.9 to 9.7] PRA, ng/ml per hour 2.4 [1.6 to 3.2] 2.3 [1.6 to 3.1] 2.4 [1.7 to 3.7] ARR 2.7 [1.8 to 4.1] 2.8 [1.9 to 4.1] 2.5 [1.4 to 4.0] Serum cortisol, nmol/l 237.3 [173.8 to 314.5] 237.3 [171 to 320] 238.7 [173.8 to 321.5] Serum creatinine, mol/l 46.9 [41.5 to 54.8] 46.9 [40.7 to 53.9] 46.4 [41.5 to 55.0] Serum K, mmol/l 4.3 [4.1 to 4.5] 4.3 [4.1 to 4.5] 4.3 [4.1 to 4.6] Serum Na, mmol/l 141 [140 to 142] 141 [140 to 142] 141 [140 to 142] UFF/Cr, nmol/nmol 5.1 [3.4 to 7.5] 4.6 [3.1 to 7.5] 5.7 [3.7 to 7.7] FENa 12 hours 0.66 [0.46 to 0.89] 0.66 [0.47 to 0.92] 0.65 [0.43 to 0.86] Values correspond to median Q 1 Q 3.*P 0.05 compared with the NH group, Mann Whitney test. SDS, standard deviation score; BMI, body mass index; DBP index, diastolic blood pressure index; FENa, fractional excretion of sodium. To convert from SI units to conventional units, divide cortisol (nmol/l)/27.59 g/dl; creatinine ( mol/l)/88.4 mg/dl; and UFF/Cr (nmol/nmol)/0.3138 g/g. To convert from conventional units to SI units, multiply SA (ng/dl) 27.743 pmol/l. To convert PRA from ng/ml per hour to g/l per hour multiply 1. NH and NN groups (Table 1). The diastolic BP index was also similar between both groups. However, the SBP index was higher in the NH group than the NN group (Table 1). Biochemical Characteristics The values of SA, PRA, ARR, serum cortisol, serum Cr, serum potassium, serum sodium, nocturnal UFF/Cr, and fractional excretion of sodium did not show any differences between the group of children with NH and the group of children with NN (Table 1). Moreover, when PRA data were analyzed according to their distribution in percentiles, we observed that PRA at the 95th and 97th percentiles was lower in the NH group than the NN group (4.9 and 6.8 ng/ml per hour versus 7.4 and 10.6 ng/ml per hour, respectively). As a consequence, the ARR at the 95th and 97th percentiles tended to be higher in the NH group (8.9 and 15.0, respectively) than the NN group (9.1 and 13.5, respectively) (Table 2). The examination of the results by gender showed differences in PRA but not in SA or ARR. In the total group, median levels of SA were similar in males and females, 7.0 (3.6 to 10.2) ng/dl (194.2 [99.8 to 282.9] pmol/l) versus 6.0 (3.2 to 8.9) ng/dl (166.5 [88.8 to 246.9] pmol/l), P 0.160. The same result was observed in the NH group, 6.6 (4.0 to 10.1) ng/dl (183 [110 to 280] pmol/l) versus 6.1 (3.3 to 8.9) ng/dl (167.8 [91.6 to 247.6] pmol/l), P 0.400; and the NN group, 7.5 (3.0 to 11.3) ng/dl (208 [83 to 313] pmol/l) versus 6.0 (3.1 to 8.8) ng/dl (166.5 [86 to 244] pmol/l), P 0.247. The levels of PRA, however, showed differences in the total group. Males had higher PRA levels than females (2.5 [1.7 to 3.5] ng/ml per hour versus 2.1 [1.3 to 3.1] ng/ml per hour; P 0.024). This same pattern was also observed in the NH group (2.6 [1.9 to 3.3] ng/ml per hour versus 1.9 [1.1 to 3.0] ng/ml per hour; P 0.005) but not in the NN group (2.5 [1.7 to 3.8] ng/ml per hour versus 2.4 [1.8 to 3.6] ng/ml per hour; P 0.749). The above differences were not reflected in ARR. In the total group, ARR was similar in males and females (2.6 [1.6 to 4.3] versus 2.7 [1.8 to 3.9]; P 0.646). The same fact was observed in the NH group (2.4 [1.8 to 4.1] versus 3.1 [2.1 to 4.2]; P 0.094), as well as the NN group (2.7 [1.5 to 4.4] versus 2.4 [1.3 to 3.6]; P 0.337). Table 2. Serum Aldosterone, Plasma Renin Activity, and ARR in the Total Group and in the Subgroups Stratified by Parental BP Status Hormones Percentile 3rd 10th 50th 85th 90th 95th 97th SA, ng/dl NH (n 113) 2.5 2.5 6.5 12.3 13.7 18.4 20.6 NN (n 98) 2.5 2.5 6.5 11.6 12.6 17.7 19.1 Total (n 211) 2.5 2.5 6.5 11.6 13.4 17.7 20.6 PRA, ng/ml NH (n 113) 0.6 0.9 2.3 3.6 3.8 4.9 6.8 per hour NN (n 98) 0.5 1.1 2.4 4.4 4.9 7.4 10.6 Total (n 211) 0.6 1.0 2.4 3.9 4.4 5.9 7.5 ARR NH (n 113) 0.9 1.5 2.8 5.4 6.9 8.9 15.0 NN (n 98) 0.6 1.0 2.5 5.3 6.2 9.1 13.5 Total (n 211) 0.8 1.2 2.7 5.3 6.3 8.7 13.1 To convert from conventional units to SI units, multiply SA (ng/dl) 27.743 pmol/l. To convert PRA from ng/ml per hour to g/l per hour multiply 1.

394 Hypertension September 2010 Downloaded from http://hyper.ahajournals.org/ by guest on May 9, 2018 A Aldosterone (ng/dl) B PRA (ng/ml*h) C ARR 100.0 10.0 1.0.0 10.0 1.0.0 100.0 10.0 1.0.0 4.0-5.9 4.0-5.9 4.0-5.9 6.0-7.9 * * 6.0-7.9 * 6.0-7.9 8.0-9.9 10.0-11.9 Age group (years) 8.0-9.9 10.0-11.9 12.0-13.9 Age group (years) 8.0-9.9 10.0-11.9 Age group (years) 12.0-13.9 14.0-16.0 14.0-16.0 12.0-13.9 14.0-16.0 Figure. Boxplot of log SA, log PRA, and log aldosterone/pra ratio grouped by age. The gray box represents normotensive subjects with hypertensive parents (NH group). The white box represents normotensive subjects with normotensive parents (NN group). The top of the box represents the 75th percentile, the bottom of the box represents the 25th percentile, and the line in the middle represents the 50th percentile. The whiskers (the lines that extend out the top and bottom of the box) represent the highest and lowest values that are not outliers or extreme values. Outliers (values that are between 1.5 and 3 times the interquartile range) are represented by circles beyond the whiskers, and extreme values are represented by stars (values that are more than 3 times the interquartile range). Correlations Between Serum Aldosterone, Plasma Renin Activity, and SA/PRA Ratio with Age Median values of SA, PRA and ARR stratified by age are showed in Figure. SA was inversely correlated with age in the total group (r 0.176; P 0.01) and the NN group (r 0.2; P 0.047) but not in the NH group (r 0.096; P 0.096). PRA was inversely correlated with age in the total group (r 0.285; P 0.001), as well as the NH and NN groups (r 0.191; P 0.043 and r 0.374, P 0.001, respectively). The ARR values did not correlate with age (P 0.153). For other association results, please see the supplemental data. Genetic Study Only 1 of the 211 subjects studied had an ARR 25. This girl was in the NH group and had an ARR of 82. Genetic analysis confirmed the chimeric gene CYP11B1/CYP11B2. Discussion This study demonstrates that the ARR in a healthy normotensive pediatric population is lower than that reported in an adult population. This suggests that PA screening in children should be done with a significantly lower cut-off value for ARR than that reported in an adult population to avoid missing patients affected by this condition. In our study, the mean ARR in healthy normotensive children with normotensive parents was under half of the ARR reported by our group in normotensive subjects from an adult Chilean population (ARR, 9.06 7.48). 16 Moreover, the group without hypertensive parents tended to have lower values of ARR than the group with hypertensive parents, which suggests that prehypertensive conditions in these children begin at an early age. Two facts support this hypothesis: (1) although the 2 groups of subjects were normotensive, the group of children with NH had a higher SBP index than those with NN, and (2) we found a healthy normotensive child in the NH group with chimeric gene (CYP11B1/CYP11B2). The pathophysiology of hypertension is not completely known, and genetic influences have been attributed in 30 to 60% of cases. 31,32 In addition, a positive family history represents a major risk factor for future hypertension in nonhypertensive offspring, 33 and the parental hypertensive antecedent predicts changes in offspring SBP during follow-up. 34 Considering that the NH group probably represents subjects with prehypertensive conditions, we choose the group of children without hypertensive parents to calculate our normal ARR reference values in the pediatric population. Alvarez- Madrazo et al 35 found that the ARR is influenced by genetic and environmental factors, and the ethnic background of the population studied should be considered. Our Chilean population is composed of 30% Hispanic-white, 65% white mestizo, and 5% Amerindian. 36 Other studies using other populations with different ethnicities should be performed to establish relevant specific reference ranges for ARR. Age-related changes in the renin-aldosterone system in normal humans are well documented. The most pronounced changes are observed at the extremes of life. 37 We found a negative correlation between age and PRA. Similar results were previously described by Wilson et al, 38 who reported that PRA and active renin concentrations were negatively correlated with age. Moreover, Fiselier et al 39 measured basal PRA, as well as active and inactive plasma renin concentrations, in 89 healthy recumbent children aged between 1 week and 16 years and found an age-related decrease for active, inactive, and total renin concentrations. In relation to aldosterone, our results are similar with other reports that demonstrated decreased aldosterone levels with age. 40 However, aldosterone did not reach a significant association with age in the NH group, which was likely due to familial antecedents of hypertension or other factors that could influence the aldosterone levels. Although a trend toward a positive correlation was demonstrated in the NN group, the correlation between age and ARR did not reach statistical significance. It is likely that the narrow age range (4 to 16 years) and the number of patients was not enough to demonstrate a significant associ-

Martinez-Aguayo et al Aldosterone/Renin Ratio in Normotensive Children 395 Downloaded from http://hyper.ahajournals.org/ by guest on May 9, 2018 ation. The BP was not significantly associated to ARR in our study, which was similar to previous findings by Li et al. 41 The percentage of body-fat mass was inversely associated with aldosterone and PRA (see supplemental data). However, this was not observed with body mass index. When the percentage of body-fat mass was controlled by age, the correlation was lost. These results suggest that changes in the body composition were not an important determinant in the aldosterone or renin levels during childhood. If we consider the age of the children enrolled in this study, it is probable that their parents were relatively young and some children with hypertensive parents could have a greater risk of heritable hypertension. However, some normotensive parents could also become hypertensive in the future. For this reason, the subdivision of the children according to the presence or absence of hypertensive parents should be taken with caution. Finally, given the fact that ARR showed a continuous increase with age within the population studied, having 1 cut-off for children and another for adults could be an oversimplification, and the ideal would be to create age-related percentile charts. However, to achieve this, we would need a larger group of normal subjects. Moreover, because many factors may play roles in ARR levels, such as ethnicity, assay methods, and environmental factors, it is necessary that each center have validated normal data for ARR. Children with a high ARR should undergo a confirmatory test to definitively confirm or exclude the diagnosis of PA. Four testing procedures (oral sodium loading, saline infusion, fludrocortisone suppression, and captopril challenge) are in common use in adults. 15 However, a validated confirmatory test in children has not been reported in the current literature. Perspectives ARR values appear to be lower in children. This should be taken into account when screening pediatric populations for PA. More studies will be necessary to validate our proposed cut-off and to determine its capacity to predict the risk of PA. Our data have contributed to knowledge of renin and aldosterone levels during childhood and should help in the development of guidelines for detection of PA as a cause of hypertension. Acknowledgments We thank Dr John C. Achermann for his critical review of this manuscript. We also thank our patients and their families. Sources of Funding This work was supported by the Chilean Grant FONDECYT 1100356 and 1070876. A.M.-A. is the recipient of grants from Becas-Chile and from the Pontificia Universidad Católica de Chile. C.A.C. is fellow of Comision Nacional de Investigacion Cientifica y Tecnologica de Chile. None. Disclosures References 1. Conn JW, Cohen EL, Rovner DR, Nesbit RM. Normokalemic primary aldosteronism. A detectable cause of curable essential hypertension. JAMA. 1965;193:200 206. 2. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243 1248. 3. Connell JM, MacKenzie SM, Freel EM, Fraser R, Davies E. A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function. Endocr Rev. 2008;29: 133 154. 4. Dunn PJ, Espiner EA. Outpatient screening tests for primary aldosteronism. Aust NZ J Med. 1976;6:131 135. 5. McKenna TJ, Sequeira SJ, Heffernan A, Chambers J, Cunningham S. Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary hyperaldosteronism. J Clin Endocrinol Metab. 1991;73:952 957. 6. Gordon R. Mineralocorticoid hypertension. Lancet. 1994;344:240 243. 7. Lins PE, Adamson U. Plasma aldosterone-plasma renin activity ratio: a simple test for primary aldosteronism. Acta Endocrinol. 1986;113: 564 569. 8. Stowasser M, Gordon RD. The aldosterone-renin ratio for screening for primary aldosteronism. Endocrinologist. 2004;14:267 276. 9. Tiu SC, Choi CH, Shek CC, Ng YW, Chan FK, Ng CM, Kong AP. The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling. J Clin Endocrinol Metab. 2005;90:72 78. 10. Seiler L, Rump LC, Schulte-Mönting J, Slawik M, Borm K, Pavenstädt H, Beuschlein F, Reincke M. Diagnosis of primary aldosteronism: value of different screening parameters and influence of antihypertensive medication. Eur J Endocrinol. 2004;150:329 337. 11. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, Young WF Jr. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;89:1045 1050. 12. Mosso L, Carvajal C, González A, Barraza A, Avila F, Montero J, Huete A, Gederlini A, Fardella CE. Primary aldosteronism and hypertensive disease. Hypertension. 2003;42:161 165. 13. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002;40:892 896. 14. Mulatero P, Dluhy RG, Giacchetti G, Boscaro M, Veglio F, Stewart PM. Diagnosis of primary aldosteronism: from screening to subtype differentiation. Trends Endocrinol Metab. 2005;16:114 119. 15. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF Jr., Montori VM. The Endocrine Society. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:3266 3281. 16. Fardella CE, Mosso L, Gomez-Sanchez C, Cortes P, Soto J, Gomez L, Pinto M, Huete A, Oestreicher E, Foradori A, Montero J. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab. 2000;85:1863 1867. 17. Lim PO, Dow E, Brennan G, Jung RT, MacDonald TM. High prevalence of primary aldosteronism in the tayside hypertension clinic population. J Hum Hypertens. 2000;14:311 315. 18. Fogari R, Preti P, Zoppi A, Rinaldi A, Fogari E, Mugellini A. Prevalence of primary aldosteronism among unselected hypertensive patients: a prospective study based on the use of an aldosterone/renin ratio above 25 as a screening test. Hypertens Res. 2007;30:111 117. 19. Sorof JM, Lai D, Turner J, Poffenbarger T, Portman RJ. Overweight, ethnicity, and the prevalence of hypertension in school-aged children. Pediatrics. 2004;113:475 482. 20. Hansen ML, Gunn PW, Kaelber DC. Underdiagnosis of hypertension in children and adolescents. JAMA. 2007;298:874 879. 21. Lurbe E, Cifkova R, Cruickshank JK, Dillon MJ, Ferreira I, Invitti C, Kuznetsova T, Laurent S, Mancia G, Morales-Olivas F, Rascher W, Redon J, Schaefer F, Seeman T, Stergiou G, Wühl E, Zanchetti A. Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens. 2009; 27:1719 1742. 22. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969;44:291 303. 23. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114:555 576. 24. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. The

396 Hypertension September 2010 Downloaded from http://hyper.ahajournals.org/ by guest on May 9, 2018 seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Hypertension. 2003;42:1206 1252. 25. Batista DL, Riar J, Keil M, Stratakis CA. Diagnostic tests for children who are referred for the investigation of Cushing syndrome. Pediatrics. 2007;120:e575 e586. 26. Kreft C, Menard J, Corvol P. Value of renin measurement, saralasin test, and acelretolol treatment in hypertension. Kidney Int. 1979;15:176 183. 27. Sealey JE, James GD, Laragh JH. Interpretation and guidelines for the use of plasma and urine aldosterone and plasma angiotensin II, angiotensinogen, prorenin, peripheral, and renal vein renin tests. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management. 2nd ed. New York, NY: Raven Press; 1995:1953 1968. 28. Montero J, Soto J, Fardella C, Foradori A, Valdés G. Medición de la actividad de renina plasmática a niveles bajos. Optimización del método. Rev Med Chil. 1998;126:151 154. 29. Jonsson JR, Klemm SA, Tunny TJ, Stowasser M, Gordon RD. A new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension. Biochem Biophys Res Commun. 1995;207: 565 571. 30. MacConnachie AA, Kelly KF, McNamara A, Loughlin S, Gates LJ, Inglis GC, Jamieson A, Connell JM, Haites NE. Rapid diagnosis and identification of cross-over sites in patients with glucocorticoid remediable aldosteronism. J Clin Endocrinol Metab. 1998;83:4328 4331. 31. Hottega JJ, Boomsma DI, Kupper N, Posthuma D, Snieder H, Willemsen G, de Geus EJ. Heritability and stability of resting blood pressure. Twin Res Hum Genet. 2005;8:499 508. 32. Levy D, DeStefano AL, Larson MG, O Donnell CJ, Lifton Rp, Gavras H, Cupples LA, Myers RH. Evidence for a gene influencing blood pressure on chromosome 17. Genome scan linkage results for longitudinal blood pressure phenotype in subjects from the Framingham heart study. Hypertension. 2000;36:477 483. 33. Stamler R, Stamler J, Riedlinger WF, Algera G, Roberts RH. Family (parental) history and prevalence of hypertension. Results of a nationwide screening program. JAMA. 1979;241:43 46. 34. Lieb W, Pencina MJ, Wang TJ, Larson MG, Lanier KJ, Benjamin EJ, Levy D, Tofler GH, Meigs JB, Newton-Ched Ch, Vasan RS. Association of parental hypertension with concentration of select biomarkers in nonhypertensive offspring. Hypertension. 2008;52:381 386. 35. Alvarez-Madrazo S, Padmanabhan S, Mayosi BM, Watkins H, Avery P, Wallace AM, Fraser R, Davies E, Keavney B, Connell JM. Familial and phenotypic associations of the aldosterone Renin ratio. J Clin Endocrinol Metab. 2009;94:4324 4333. 36. Medina E, Kaempffer AM. Elementos de Salud Pública. Biblioteca Digital de la Universidad de Chile. Available at http://mazinger. sisib.uchile.cl/repositorio/lb/ciencias_quimicas_y_farmaceuticas/ medinae/cap2/5b6.html. Accessed 22 March, 2010. 37. Bauer JH. Age-related changes in the renin-aldosterone system. Physiological effects and clinical implications. Drugs Aging. 1993;3:238 245. 38. Wilson DM, Stevenson DK, Luetscher JA. Plasma prorenin and renin in childhood and adolescence. Am J Dis Child. 1988;142:1070 1072. 39. Fiselier T, Derkx F, Monnens L, Van Munster P, Peer P, Schalekamp M. The basal levels of active and inactive plasma renin concentration in infancy and childhood. Clin Sci. 1984;67:383 387. 40. Dillon MJ, Ryness JM. Plasma renin activity and aldosterone concentration in children. BMJ. 1975;4:316 319. 41. Li R, Richey PA, DiSessa TG, Alpert BS, Jones DP. Blood aldosteroneto-renin ratio, ambulatory blood pressure, and left ventricular mass in children. J Pediatr. 2009;155:170 175.

ONLINE SUPPLEMENTAL DATA ALDOSTERONE, PLASMA RENIN ACTIVITY AND ALDOSTERONE-TO-RENIN RATIO IN A NORMOTENSIVE HEALTHY PEDIATRIC POPULATION Authors and institutions: Alejandro Martinez-Aguayo (1), Marlene Aglony (1), Carmen Campino (2), Hernan Garcia (1), Rodrigo Bancalari (1), Lillian Bolte (1), Carolina Avalos (3), Carolina Loureiro (1), Cristian Carvajal (2), Alejandra Avila (4), Viviana Perez (1), Andrea Inostroza (5), Carlos Fardella (2). 1 Department of Pediatrics, Pontificia Universidad Catolica de Chile. Santiago, Chile. 2 Department of Endocrinology, Pontificia Universidad Catolica de Chile. Santiago, Chile. 3 Department of Pediatrics, Universidad de Antofagasta, Chile. 4. Institute of Maternal and Child Research (IDIMI), Faculty of Medicine, University of Chile, Santiago, Chile. 5. Department of Nephrology, Pontificia Universidad Catolica de Chile. Santiago, Chile. Short title: Aldosterone-renin ratio in normotensive children Name and address of person from whom reprints should be requested: Prof. Carlos Fardella, MD Endocrinology Department School of Medicine Pontificia Universidad Católica de Chile Lira 85, piso 5, Santiago, CHILE Postal code: 8330074 PHONE: (56-2) 354-3095 FAX: (56-2) 638-5675 E-mail: cfardella@med.puc.cl

EXPANDED METHODS Blood Pressure Index The BP index was determined using the observed BP / 50th percentile BP value for gender, age and stature using the normal values reported. For example: to calculate the BP index for an 11 year old girl with height on the 10 th percentile and systolic blood pressure (SBP) of 120 mmhg and diastolic blood pressure (DBP) of 74 mmhg: 1.- The SBP and DBP 50 th percentile for an 11 year old girl on the 10 th percentile are 101 mmhg and 60 mmhg, respectively. 2.- The SBP index = SBP observed / SBP in 50th percentile = 120 mmhg / 101 mmhg = 1.18 The DBP index = DBP observed / DBP in 50th percentile = 74 mmhg / 60 mmhg = 1.23

EXPANDED RESULTS Correlations between clinical and biochemical parameters SA was inversely correlated with the percentage of body-fat mass in the total group (r= -0.139; p=0.049); however, this association was not observed when partial-correlation controlling by age was performed (p=0.201). Moreover, the Tanner development state was not associated with SA (Spearman's rho; p=0.271). There were no correlations between SA and SBP index or DBP index and FENa (12 h) in the total group or the NH and NN groups (Table S1). In the total group, the Tanner development state was inversely associated with PRA (Spearman's rho= -0.306; p=0.001); however, this association was not observed after we controlled for age (p= 0.987). In the total group, the percentage of body-fat mass was inversely associated with PRA (r= -0.155; p= 0.028), but this association was not observed when partial correlation was performed controlling for age (p=0.816). There were no correlations between PRA and SBP index or DBP index and FENa (12 h) in the total group or the NH and NN groups (Table S1). The ARR correlate with the Tanner development state (Spearman's rho=0.192, p=0.039). This association did not persist, however, after controlling for age (p=0.33). There were no correlations between ARR and SBP index or DBP index and FENa (12 h) in the total group or in the NH and NN groups (Table S1). The serum cortisol in the total group was not associated with age (p=0.454), BMI (p=0.166), the percentage of body-fat mass (p=0.074), SBP index (p=0.385) or DBP index (p=0.894). The same results were observed in the NH and NN groups (data not shown). The UFF/Cr in the total group was not associated with age (p=0.454), BMI (p=0.905), the percentage of body-fat mass (p=0.284), SBP index (p=0.203) or DBP index (p=0.929). The same results were observed in the NH and NN groups (Data not shown).

Table S1. Correlation between aldosterone, plasma renin activity, and ARR with age, BMI, body-fat percentage, and SBP and DBP indices in the total group and in the subgroup studies. Correlation coefficient Total group NH group NN group r p r p r p Aldosterone Age (y) -0.176 0.010-0.157 0.096-0.202 0.047 BMI (percentile) -0.007 0.922-0.009 0.925-0.003 0.979 BFM (%) -0.139 0.049-0.143-0.141-0.134 0.199 SBP index -0.009 0.893 0.119 0.207-0.158 0.120 DBP index -0.015 0.831 0.095 0.317-0.169 0.097 FENa 12 h 0.001 0.985 0.138 0.150-0.112 0.257 PRA Age (y) -0.285 0.001-0.191 0.043-0.374 <0.001 BMI (percentile) -0.044 0.525-0.047 0.622-0.048 0.638 BFM (%) -0.155 0.028-0.165 0.089-0.149 0.152 SBP index 0.002 0.981 0.119 0.208-0.082 0.423 DBP index 0.046 0.507 0.097 0.306-0.011 0.912 FENa 12 h -0.101 0.149-0.004 0.970-0.183 0.072 ARR Age (y) 0.099 0.153 0.023 0.810 0.167 0.101 BMI (percentile) 0.033 0.636 0.033 0.730 0.040 0.695 BFM (%) 0.016 0.820 0.013 0.898 0.023 0.826 SBP index -0.006 0.925 0.005 0.958-0.055 0.590 DBP index -0.053 0.445 0.002 0.983-0.126 0.218 FENa 12 h 0.073 0.298 0.145 0.128 0.071 0.489 BMI, body mass index; SBP index, systolic blood pressure index; DBP index, diastolic blood pressure index, ARR, aldosterone/plasma renin activity ratio; FENa, fractional excretion of sodium; NH, normotensive with hypertensive parents; and NN, normotensive with normotensive parents.

FIGURE S1. Distribution of aldosterone/renin ratio (ARR) in normotensive children with hypertensive or normotensive parents. Upper panel: distribution of aldosterone/renin ratio (ARR) in normotensive children with hypertensive parents (n=113). To put the results in the same scale as the lower panel, a value of ARR=82 was omitted. Lower panel: distribution of aldosterone/renin ratios in normotensive children with normotensive parents (n=98).